Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Sackstein, M.D.,Ph.D.

Concepts

This page shows the publications Robert Sackstein has written about Middle Aged.
Connection Strength

0.038
  1. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med. 2008 Feb; 14(2):181-7.
    View in: PubMed
    Score: 0.008
  2. In vitro adherence of lymphocytes to dermal endothelium under shear stress: implications in pathobiology and steroid therapy of acute cutaneous GVHD. Blood. 2003 Jan 15; 101(2):771-8.
    View in: PubMed
    Score: 0.006
  3. Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation, and ERK1/2 and p38 MAPK activation. Mol Oncol. 2018 05; 12(5):579-593.
    View in: PubMed
    Score: 0.004
  4. Lymphocyte adhesion to psoriatic dermal endothelium is mediated by a tissue-specific receptor/ligand interaction. J Invest Dermatol. 1988 Nov; 91(5):423-8.
    View in: PubMed
    Score: 0.002
  5. Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol. 2008 Apr; 36(4):464-72.
    View in: PubMed
    Score: 0.002
  6. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2005 Feb; 128(3):351-9.
    View in: PubMed
    Score: 0.002
  7. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant. 2003 Jun; 9(6):373-82.
    View in: PubMed
    Score: 0.001
  8. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2003 May; 9(5):320-9.
    View in: PubMed
    Score: 0.001
  9. Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and a haploidentical related allogeneic bone marrow transplant. Cytokines Cell Mol Ther. 2002 Dec; 7(2):43-7.
    View in: PubMed
    Score: 0.001
  10. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 2002 Nov 27; 74(10):1405-9.
    View in: PubMed
    Score: 0.001
  11. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(11):604-12.
    View in: PubMed
    Score: 0.001
  12. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. Bone Marrow Transplant. 2000 Jan; 25(1):19-24.
    View in: PubMed
    Score: 0.001
  13. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 2000; 6(3A):309-20.
    View in: PubMed
    Score: 0.001
  14. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(8):891-5.
    View in: PubMed
    Score: 0.001
  15. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(8):897-902.
    View in: PubMed
    Score: 0.001
  16. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation. 1999 Aug 27; 68(4):480-4.
    View in: PubMed
    Score: 0.001
  17. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999 May 22; 353(9166):1755-9.
    View in: PubMed
    Score: 0.001
  18. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant. 1997 Oct; 20(8):653-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.